1.A ranar 12 ga Mayu, DPRK ta ba da rahoto a karon farko cewa an sami bullar cutar Omicron a China.Tare da karuwar yawan masu fama da zazzabi, har ila yau za a yi tasiri kai tsaye kan cinikin magungunan gargajiyar kasar Sin da shigo da kayayyaki.
Ta hanyar bincike na baya-bayan nan game da manyan kasuwannin magunguna guda huɗu, dandalinmu ya gano cewa nau'ikan kayan magani masu alaƙa da Koriya ta Arewa, irin su guntun kasusuwa, tushen wake na Arewa, farar fata, farar Wei, Ligusticum, pangshanlong, da sauransu, sun ƙaru da digiri daban-daban. a cikin makon da ya gabata, kuma wasu nau'ikan sun karu da fiye da kashi 50%.
2.Antidepressant TOP10 ya fita!Iri biliyan 1.8 ne ke jagorantar haɓakar samfuran cikin gida.
Kwanan nan, labarin nasarar nasarar asibiti na kashi III ya fito ne daga magungunan antidepressants guda biyu.Bisa kididdigar da aka yi ta intanet, a shekarar 2021, an sayar da magungunan kashe gobara da magunguna masu guba a cibiyoyin kiwon lafiyar jama'a na kasar Sin ya zarce yuan biliyan 8.7;Pfizer ya lashe matsayi na farko a karon farko, kuma Jingwei Pharmaceutical ya shiga saman uku a karon farko;Allunan Escitalopram oxalate sun mamaye jerin akai-akai.Siyar da allunan agomelatine ya karu da kashi 72.74%, kuma tallace-tallacen nau'ikan nau'ikan nau'ikan nau'ikan nau'ikan sun fadi sosai.An kiyasta nau'ikan nau'ikan 20, kuma Fosun, Kelun da Huahai sun jagoranci jerin;Sabbin magunguna na aji 12 suna kan haɓakawa, waɗanda suka haɗa da LVYE, hausen, xinlitai, da sauransu.
3.Kasuwar magungunan rage lipid na jini na 26billion ya faɗi, kuma PCSK9 antibody, wanda aka yi niyya na inshorar likita, ya ƙara ƙarfi.
Tare da bullar sabbin magunguna a duk faɗin duniya, kasuwar magungunan hypolipidemic ta China tana canzawa.Dangane da bayanan Intanet, a cikin 2019, sikelin kasuwa na magungunan hypolipidemic a cibiyoyin kiwon lafiyar jama'a na kasar Sin ya zarce yuan biliyan 26.Koyaya, tare da ƙarin kimantawa na statins guda huɗu da cikakken aiwatar da sayayya ta tsakiya, farashin magungunan rage ƙwayar jini ya nuna yanayin raguwar farashin.
4.Sabuwar nau'ikan guda na 2billion na maganin cututtukan zuciya na baka "Canjin mallakar" an haife shi.A cikin 'yan shekarun nan, tare da tsufa na yawan jama'a da karuwa a hankali na yawan cututtukan cututtuka, kasuwar magungunan da ke da alaƙa ta jawo hankali sosai.Bisa kididdigar da MI Nei ta fitar, a shekarar 2021, sikelin sayar da magunguna na maganin ciwon suga na baki a cikin cibiyoyin kiwon lafiyar jama'a na kasar Sin ya zarce Yuan biliyan 20.Daga cikin manyan samfuran 10, samfuran sayayya a tsakiya sun mamaye kujeru 6, kuma tallace-tallacen samfuran 8 ya wuce yuan biliyan 1.Allunan Metformin hydrochloride sun hau gadon sarautar "yane na farko", kuma allunan dagliejing sun wuce yuan biliyan 2 a karon farko, sun kai na uku.Tun daga wannan shekarar, an amince da magungunan hypoglycemic na baka don tallatawa.A halin yanzu, magungunan hypoglycemic na baka 37 (fiye da lambobin karɓa sama da 150) ana yin nazari, daga cikinsu allunan dagliejing, allunan weigliptin da allunan sitagliptin phosphate sun fi shahara;Babu wani nau'in magunguna da aka yarda da samfuran guda shida, gami da kaglitazone metformin ci gaba da sakin allunan, rubiprostone capsules, da allunan tegagliptin hydrobromide, waɗanda suka haɗa da kamfanoni da yawa, irin su Sichuan Kelun Pharmaceutical, Nanjing Zhengda Tianqing Pharmaceutical, Lepu Pharmaceutical da dai sauransu.
5.CDC ta ba da shawarwarin lafiyar cutar sankarau: babu haɗarin kamuwa da cuta a tsakanin yawan jama'a a China.
Bisa ga asusun hukuma na wechat na CDC, tun daga watan Mayun 2022, an sami adadin masu kamuwa da cutar sankarau a wasu ƙasashe a wuraren da ba su da cutar, kuma an sami yaduwa tsakanin mutane.Don kare lafiyar 'yan kasar Sin, CDC ta gabatar da shawarwarin kiwon lafiya masu dacewa.Daga cikin su, cutar kyandar biri cuta ce mai kau da kai, kuma mafi yawansu suna da kyakkyawan hasashen.A halin yanzu, babu takamaiman maganin cutar kyandar biri a kasar Sin.Babu wani rahoton bullar cutar kyandar biri a kasar Sin, kuma ba a samu kwayar cutar kyandar biri a cikin namun daji ko keɓe masu shiga ba.Yawan jama'a ba shi da haɗarin kamuwa da cuta.
6.Halayen fasaha da fa'idodin ƙwayar ƙwayar ƙwayar ƙwayar cuta ta ƙwayar cuta (HDRA).
Ƙwararren ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta (HDRA) a cikin iyakokin jagororin NCCN ya gane haɗin daidaitattun jiyya da keɓancewa, yana inganta ƙa'idodin, rage sake dawowa na ciwon tumo bayan tiyata kuma yana tsawaita rayuwa.
7.Kasuwar cephalosporin ta fadi ta hanyar Chengdu Beite biliyan 57 sabon echelon biliyan 1!
Ana amfani da Cephalosporins akai-akai a cikin magungunan asibiti da kuma Top1 sub category na tsarin rigakafi na ƙwayoyin cuta.A cikin 'yan shekarun nan, cephalosporins suma sun zama "abokin ciniki akai-akai" na sayayya na ƙasa.A karkashin tasirin manufofin da yawa, sikelin tallace-tallace na cephalosporins a cikin tashoshin cibiyoyin kiwon lafiya na jama'a a kasar Sin ya sake faduwa a shekarar 2021, ya fadi kasa da yuan biliyan 57.Tallace-tallacen alluran sun farfado kuma adadinsu ya karu.Tsarin masana'antu da yawa na nau'ikan gida waɗanda suka shiga tarin ƙasa ya canza sosai.Kasuwancin magunguna na gabaɗaya yana haɓaka "wurin sarari";A cikin 'yan shekarun nan, da R & D shugabanci na cikin gida Pharmaceutical Enterprises ya mayar da hankali a kan sabon sashi siffofin fili shirye-shirye da foda ruwa biyu jamhuriyar bags, da kuma da dama m sabon kayayyakin suna shirye su je.
JinDun Medicalyana da haɗin gwiwar bincike na kimiyya na dogon lokaci tare da fasahar kere-kere tare da jami'o'in kasar Sin.Tare da wadataccen albarkatun kiwon lafiya na Jiangsu, tana da dangantakar kasuwanci ta dogon lokaci tare da Indiya, kudu maso gabashin Asiya, Koriya ta Kudu, Japan da sauran kasuwanni.Hakanan yana ba da sabis na kasuwa da tallace-tallace a cikin gabaɗayan tsari daga matsakaici zuwa ƙãre samfurin API.Yi amfani da tarin albarkatun Yangshi Chemical a cikin sinadarai na fluorine don samarwasabis na gyare-gyaren sinadarai na musammanga abokan tarayya.Samar da sabbin abubuwa da ayyukan bincike na ƙazanta don ƙaddamar da abokan ciniki.
Lokacin aikawa: Nuwamba-10-2022